About Us | Contact Us | Editorial Board | About Haymarket Media

RSS | Login | Register

The more we know about our visitors, the easier it will be for us to publish everything you want to see.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Vinblastine for injection

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare Vinblastine for injection to:

Generic Name for Vinblastine for injection

Vinblastine (as sulfate) 10mg/vial; lyophilized pwd for IV inj or infusion after reconstitution.

Legal Classification:

Pharmacological Class for Vinblastine for injection

Antimicrotubule agent.

Manufacturer of Vinblastine for injection

Bedford Laboratories

Indications for Vinblastine for injection

Less frequently responsive: choriocarcinoma resistant to other chemotherapy.

Other Indications for Vinblastine for injection

Breast cancer

Kaposi's sarcoma

Leukemias, lymphomas, and other hematologic cancers

Prostate and other male cancers

Adult dose for Vinblastine for injection

See literature. Give by IV once weekly. 1^st dose: 3.7mg/m² as a single dose, continue to increase dose by increments (2^nd dose: 5.5mg/m², 3^rd dose: 7.4mg/m², 4^th dose: 9.25mg/m², 5^th dose: 11.1mg/m², max dose: 18.5mg/m²) until WBC 3,000cells/mm³ reached, stop at this dose, then administer a dose one increment smaller at weekly intervals for maintenance. Usual weekly dosage: 5.5–7.4mg/m². Do not give the next dose, even if 7 days have elapsed, unless WBC ≥4,000cells/mm³. If oncolytic effect occurs before leukopenia, do not increase the size of subsequent doses. Hepatic impairment: reduce dose by 50% if serum bilirubin >3mg/100mL.

Children's dosing for Vinblastine for injection

Not recommended.

Also:

Vinblastine injection

Contraindications for Vinblastine for injection

Significant granulocytopenia (unless result of disease being treated). Bacterial infections (treat first).

Warnings/Precautions for Vinblastine for injection

For IV use only; fatal if given intrathecally. Hepatic impairment. Avoid in elderly with cachexia or ulcerated skin; or in patients with malignant-cell infiltration of the bone marrow. Pre-existing pulmonary dysfunction. Progressive dyspnea requiring chronic therapy (do not re-administer). Ischemic cardiac disease. Bone marrow suppression; monitor WBC before and during treatment. Avoid contamination of the eyes or injecting into an extremity with poor circulation (thrombosis possible). Avoid extravasation. Pregnancy (Cat.D), nursing mothers: not recommended.

Interactions for Vinblastine for injection

May be potentiated by CYP3A inhibitors (eg, erythromycin). Antagonizes phenytoin.

Adverse Reactions for Vinblastine for injection

Leukopenia, alopecia, GI upset, paresthesias, malaise, pain; dyspnea, severe bronchospasm.

How is Vinblastine for injection supplied?

Pwd—10
Soln—1

Related Disease:

Cancer, breast

Cancer, placenta

Cancer, testicular

Hodgkin's disease

Kaposi's sarcoma

Letterer-Siwe disease

Lymphoma, histiocytic

Lymphoma, lymphocytic

Mycosis fungoides~antineoplastics

Data provided by the Monthly Prescribing Reference (MPR) Hematology/Oncology Edition.

Adjuvant Radiochemotherapy Has Lasting Benefit in Gastric Cancer

May 18, 2012

Patients with gastric cancer who undergo resection show survival benefit 10 years later.

Fertility-Related Information Urgently Needed for Female Patients with Cancer

Debra Hughes May 18, 2012

Young adult males and females with cancer receive vastly different amounts of fertility-related and fertility preservation information.

STAT3 Mutations ID'd in Rare Lymphoproliferative Disorder

May 18, 2012

Four specific mutations in SH2 domain seen in T-cell large granular lymphocytic leukemia.

Genetic Profiling Improves Prognosis of Uveal Melanoma

James Netterwald, PhD May 18, 2012

Gene expression profiling (GEP) and chromosomal analysis show prognostic value in patients with uveal melanoma.

Bisphosphonates Cut Skeletal Morbidity in Multiple Myeloma

May 18, 2012

Zoledronate superior to placebo or etidronate for improving overall survival.

ADRIAMYCIN SOLUTION

Oncology > Breast cancer

Doxorubicin HCl 2mg/mL; soln for IV inj.

Methotrexate for injection

Oncology > Breast cancer

Methotrexate 1gram/vial; pwd for IV, IM, intra-arterial, or intrathecal administration after dilution; preservative-free.

Methotrexate for injection

Oncology > Head and neck cancer

Methotrexate 1gram/vial; pwd for IV, IM, intra-arterial, or intrathecal administration after dilution; preservative-free.

VINCASAR PFS

Oncology > Leukemias, lymphomas, and other hematologic cancers

Vincristine sulfate 1mg/mL; soln for IV inj; contains mannitol; preservative-free.

ZOLADEX

Oncology > Breast cancer

Goserelin (as acetate) 3.6mg; SC implant.

Oncology > Cytoprotective and supportive care agents

Bisphosphonates (eg, Aredia, Zometa) may inhibit the activation of cancer-associated proteins through the suppression of geranyl-geranylation and farnesylation or inhibit ...
more »

'Teachable Moments' for Smoking Cessation in Patients Diagnosed with Cancer Underutilized

Debra Hughes February 16, 2012

Less than one-fifth (18.1%) of healthcare providers reported high levels of confidence in their ability to counsel patients with cancer who smoke to quit smoking, a survey published in The Oncologist online February 14 has found.